Instil Bio (TIL) and ImmuneOnco Biopharmaceuticals said Thursday that they expect to complete enrollment in the mid-stage trial of their non-small cell lung cancer drug IMM2510/AXN-2510, or `2510, for multiple solid tumors in China by Q3.
The companies said they expect initial safety and efficacy data from the study, which is testing `2510 in combination with chemotherapy, in H2.
The companies said that, in parallel, they plan to begin a US phase 1b/2 trial of `2510 monotherapy in relapsed or refractory solid tumors later this year.
A late-stage trial of `2510 in combination with chemotherapy is expected to begin in mid-2026 in China, the companies said.
Shares of the company were up over 5.4% in recent Thursday premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。